EP4048291A4 - COMPOSITIONS AND METHODS FOR IN VITRO ACTIVATION AND EXPANSION OF SERIAL KILLER T CELL POPULATIONS AND FOR PASSIVE IMMUNIZATION OF A CANCER PATIENT WITH TUMOR CELL KILLING CELLS - Google Patents

COMPOSITIONS AND METHODS FOR IN VITRO ACTIVATION AND EXPANSION OF SERIAL KILLER T CELL POPULATIONS AND FOR PASSIVE IMMUNIZATION OF A CANCER PATIENT WITH TUMOR CELL KILLING CELLS Download PDF

Info

Publication number
EP4048291A4
EP4048291A4 EP20879429.7A EP20879429A EP4048291A4 EP 4048291 A4 EP4048291 A4 EP 4048291A4 EP 20879429 A EP20879429 A EP 20879429A EP 4048291 A4 EP4048291 A4 EP 4048291A4
Authority
EP
European Patent Office
Prior art keywords
killer
compositions
expansion
methods
cancer patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20879429.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4048291A1 (en
Inventor
Frank BORRIELLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alloplex Biotherapeutics
Original Assignee
Alloplex Biotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/660,442 external-priority patent/US10731128B2/en
Application filed by Alloplex Biotherapeutics filed Critical Alloplex Biotherapeutics
Publication of EP4048291A1 publication Critical patent/EP4048291A1/en
Publication of EP4048291A4 publication Critical patent/EP4048291A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20879429.7A 2019-10-22 2020-10-21 COMPOSITIONS AND METHODS FOR IN VITRO ACTIVATION AND EXPANSION OF SERIAL KILLER T CELL POPULATIONS AND FOR PASSIVE IMMUNIZATION OF A CANCER PATIENT WITH TUMOR CELL KILLING CELLS Pending EP4048291A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/660,442 US10731128B2 (en) 2016-11-22 2019-10-22 Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
PCT/US2020/056698 WO2021081115A1 (en) 2019-10-22 2020-10-21 Compositions and methods for in vitro activation and expansion of serial killer t cell populations and passive immunization of a cancer patient with tumor cell killing cells

Publications (2)

Publication Number Publication Date
EP4048291A1 EP4048291A1 (en) 2022-08-31
EP4048291A4 true EP4048291A4 (en) 2024-01-17

Family

ID=75619361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20879429.7A Pending EP4048291A4 (en) 2019-10-22 2020-10-21 COMPOSITIONS AND METHODS FOR IN VITRO ACTIVATION AND EXPANSION OF SERIAL KILLER T CELL POPULATIONS AND FOR PASSIVE IMMUNIZATION OF A CANCER PATIENT WITH TUMOR CELL KILLING CELLS

Country Status (8)

Country Link
EP (1) EP4048291A4 (https=)
JP (1) JP7752424B2 (https=)
KR (1) KR20220103928A (https=)
AU (1) AU2020371619A1 (https=)
CA (1) CA3154876A1 (https=)
IL (1) IL292355A (https=)
MX (1) MX2022004772A (https=)
WO (1) WO2021081115A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113403274B (zh) * 2021-06-28 2023-11-10 上海睿臻迈生物医疗科技有限公司 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2024221005A2 (en) * 2023-04-21 2024-10-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for inhibiting resistance to immune blockade inhibitor therapy
CN116970562B (zh) * 2023-09-22 2024-01-02 北京翊博生物集团有限公司 一种抗原特异性t细胞的制备方法及其在免疫治疗中的应用
CN119320750A (zh) * 2024-10-15 2025-01-17 南开大学 Tnfsf15蛋白在制备促进肥大细胞激活的产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004201A1 (en) * 2009-07-10 2011-01-13 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
WO2018098279A1 (en) * 2016-11-22 2018-05-31 Alloplex Biotherapeutics Allogenic tumor cell vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231204A1 (en) * 2000-01-27 2001-08-07 Sidney Kimmel Cancer Center Genetically engineered tumor cell vaccines
US7087225B2 (en) * 2001-08-16 2006-08-08 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
US20180267024A1 (en) * 2015-06-08 2018-09-20 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004201A1 (en) * 2009-07-10 2011-01-13 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
WO2018098279A1 (en) * 2016-11-22 2018-05-31 Alloplex Biotherapeutics Allogenic tumor cell vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOI IL-KYU ET AL: "Mechanism of EBV inducing anti-tumour immunity and its therapeutic use", NATURE, vol. 590, no. 7844, 23 December 2020 (2020-12-23), pages 157 - 162, XP037356631, DOI: 10.1038/S41586-020-03075-W *
MONTAGNA D ET AL: "Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 12, 1 December 2001 (2001-12-01), pages 3359 - 3366, XP002330525, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V98.12.3359 *
See also references of WO2021081115A1 *

Also Published As

Publication number Publication date
CA3154876A1 (en) 2021-04-29
JP7752424B2 (ja) 2025-10-10
EP4048291A1 (en) 2022-08-31
JP2022553411A (ja) 2022-12-22
MX2022004772A (es) 2022-07-19
IL292355A (en) 2022-06-01
AU2020371619A1 (en) 2022-05-12
KR20220103928A (ko) 2022-07-25
WO2021081115A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EP4048291A4 (en) COMPOSITIONS AND METHODS FOR IN VITRO ACTIVATION AND EXPANSION OF SERIAL KILLER T CELL POPULATIONS AND FOR PASSIVE IMMUNIZATION OF A CANCER PATIENT WITH TUMOR CELL KILLING CELLS
US20230139588A1 (en) Methods of preparing anti-human papillomavirus antigen t cells
Campoli et al. Functional and clinical relevance of chondroitin sulfate proteoglycan 4
Vuckovic et al. Bone marrow transplantation generates T cell–dependent control of myeloma in mice
WO2018005521A3 (en) Cell culture chambers and methods of use thereof
EP3886877A4 (en) METHODS FOR SIMULTANEOUS EXPANSION OF SEVERAL IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES SAME IN CANCER IMMUNOTHERAPY
EP3516043A1 (en) T cell expansion method
Hu et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma
EP3426263A4 (en) METHOD AND ARTICLE FOR THE DELIVERY OF LIVABLE CELLS IN SOLID TISSUE
RU2014110897A (ru) Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
JP2004536615A5 (https=)
US20210213066A1 (en) Improved cell therapy compositions for hematopoietic stem cell transplant patients
MA56130A (fr) Procédés de culture cellulaire et compositions pour la production d'anticorps
EP2593115A4 (en) Treatment of t-cell mediated immune disorders
Slaats et al. Adenosine A2a receptor antagonism restores additive cytotoxicity by cytotoxic T cells in metabolically perturbed tumors
MX2022005086A (es) Anticuerpos anti-cd73 inmunomoduladores y usos de estos.
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
RU2016102172A (ru) Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
CN108835051A (zh) 利用淋巴瘤细胞株所构建的免疫缺陷裸鼠模型
Schirrmacher Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential
US20200323922A1 (en) Method for treating a side effect of immunotherapy
EP4041298A4 (en) In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
Yoon et al. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR)
EP3228701A1 (en) Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
Li et al. Tumor‐infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220407

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231214

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20231208BHEP

Ipc: C12N 5/078 20100101ALI20231208BHEP

Ipc: A61P 37/04 20060101ALI20231208BHEP

Ipc: A61P 37/02 20060101ALI20231208BHEP

Ipc: A61K 35/17 20150101ALI20231208BHEP

Ipc: A61P 35/00 20060101ALI20231208BHEP

Ipc: A61K 39/00 20060101ALI20231208BHEP

Ipc: A61K 35/12 20150101AFI20231208BHEP